Solid lipid nanoparticles as drug carriers for topical glucocorticoids

被引:149
作者
Maia, CS
Mehnert, W
Schäfer-Korting, M
机构
[1] Free Univ Berlin, Dept Pharmacol & Toxicol, D-14195 Berlin, Germany
[2] Free Univ Berlin, Dept Pharmaceut Technol Biopharm & Biotechnol, D-14195 Berlin, Germany
关键词
prednicarbate; benefit-risk ratio; solid lipid nanoparticles; dermal absorption; drug targeting;
D O I
10.1016/S0378-5173(99)00413-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent investigations both in vitro and in human subjects proved the benefit/risk ratio of prednicarbate (PC) to exceed those of halogenated topical glucocorticoids about 2-fold. To obtain a further highly desired increase by drug targeting to viable epidermis. PC was incorporated into solid lipid nanoparticles (SLN). Keratinocyte and fibroblast monolayer cultures, reconstructed epidermis and excised human skin served to evaluate SLN toxicity and PC absorption. Well-tolerated preparations (e.g. cellular viability 94.5%, following 18 h incubation of reconstructed epidermis) were obtained. PC penetration into human skin increased by 30% as compared to PC cream, permeation of reconstructed epidermis increased even 3-fold. The present study shows the great potential of SLN to improve drug absorption by the skin. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:165 / 167
页数:3
相关论文
共 8 条
[1]   Use of a serum-free reconstituted epidermis as a skin pharmacological model [J].
Doucet, O ;
Robert, C ;
Zastrow, L .
TOXICOLOGY IN VITRO, 1996, 10 (03) :305-313
[2]   Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin [J].
Gysler, A ;
Kleuser, B ;
Sippl, W ;
Lange, K ;
Korting, HC ;
Höltje, HD ;
Schäfer-Korting, M .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1386-1391
[3]   Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts [J].
Gysler, A ;
Lange, K ;
Korting, HC ;
SchaferKorting, M .
PHARMACEUTICAL RESEARCH, 1997, 14 (06) :793-797
[4]   Prednicarbate versus conventional topical glucocorticoids:: Pharmacodynamic characterization in vitro [J].
Lange, K ;
Gysler, A ;
Bader, M ;
Kleuser, B ;
Korting, HC ;
Schäfer-Korting, M .
PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1744-1749
[5]  
Mezei M., 1994, J PHARM SCI, V9, P1189
[6]  
MULLER RH, 1995, EUR J PHARM BIOPHARM, V41, P62
[7]   PREDNICARBATE ACTIVITY AND BENEFIT RISK RATIO IN RELATION TO OTHER TOPICAL GLUCOCORTICOIDS [J].
SCHAFERKORTING, M ;
KORTING, HC ;
KERSCHER, MJ ;
LENHARD, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (04) :448-456
[8]  
zur Muhlen A, 1998, PHARMAZIE, V53, P552